A Study of Familial and Genetic Aspects of Adult T-Cell: Leukemia/Lymphoma , Tropical Spastic Paraparesis, and Infective Dermatitis
NCT00340821 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 1800
Last updated 2017-07-02
Summary
Doctors of the University of West Indies, the Caribbean Epidemiology Center (CAREC) and the National Cancer Institute have been studying the epidemiology of HTLV-I and its role in the etiology and pathogenesis of adult T-cell leukemia/lymphoma (ALT), and aggressive T-cell lymphoma. The purpose of the current study is to evaluate familial and genetic aspects of ATL and its relationship to two other HTLV-I related conditions, HTLV-I associated myelopathy also known as tropical spastic paraparesis (HAM/TSP), and infective dermatitis. Enrollment of infective dermatitis cases was recently added and the disease entity is thought to be a harbinger for later development of either ATL or HAM/TSP. The purpose of this study is to interview patients with these conditions and perform laboratory studies (specifically, HLA and other viral or genetic studies) to better understand these diseases and their relationship to the HTLV-1 virus and the family history and genetic factors that may be involved as well.
Conditions
- HTLV-I
Sponsors & Collaborators
-
National Cancer Institute (NCI)
lead NIH
Eligibility
- Min Age
- 2 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 1993-05-17
- Completion
- 2011-03-01
Countries
- Jamaica
Study Locations
More Related Trials
-
High Risk Adult T-cell Leukemia/Lymphoma (ATLL-HR) and Allogeneic Transplant
NCT01941680 ·Status: COMPLETED
-
Treatment of Tac-Expressing Cutaneous T-Cell Lymphoma (CTCL) and Adult T-Cell Leukemia (ATL) With Yttrium-90 Radiolabeled Anti-Tac
NCT00001249 ·Status: COMPLETED ·Phase: PHASE1
-
A Registry for People With T-cell Lymphoma
NCT05978141 ·Status: RECRUITING
-
Consolidation With Loncastuximab Tesirine After a Short Course of Immunochemotherapy in BTKi-treated (or Intolerant) Relapsed/Refractory Mantle Cell Lymphoma Patients.
NCT05249959 ·Status: RECRUITING ·Phase: PHASE2
-
Comprehensive Oncology Measures for Peripheral T-cell Lymphoma Treatment Registry
NCT01110733 ·Status: COMPLETED
-
Patient-individualized Peptide Vaccination Based on Tumor-specific Mutations in Children and Young Adults With Primary/Relapsed ALL
NCT03559413 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
A Study to Evaluate the Treatment of Previously Untreated B-Cell Chronic Lymphocytic Leukemia (B-CLL)
NCT00302861 ·Status: TERMINATED ·Phase: PHASE1/PHASE2
-
Observational Study on the Occurrence of Hepatosplenic T-cell Lymphoma in Patients of Netherlands
NCT00731536 ·Status: COMPLETED
-
Registry of Relapsed/Refractory T-cell Acute Lymphoblastic Leukemia
NCT05832125 ·Status: UNKNOWN
-
Ro Plus CHOEP as First Line Treatment Before HSCT in Young Patients With Nodal Peripheral T-cell Lymphomas
NCT02223208 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE1/PHASE2
-
Immunotherapy in Peripheral T Cell Lymphoma - the Role of Alemtuzumab in Addition to Dose Dense CHOP
NCT00725231 ·Status: UNKNOWN ·Phase: PHASE3
-
A Study of YM155 Plus Rituximab in Subjects With Non-Hodgkin's Lymphoma Who Have Received Prior Treatment
NCT01007292 ·Status: COMPLETED ·Phase: PHASE2
-
Subcutaneous Recombinant Human IL-15 (s.c. rhIL-15) and Alemtuzumab for People With Refractory or Relapsed Chronic and Acute Adult T-cell Leukemia (ATL)
NCT02689453 ·Status: COMPLETED ·Phase: PHASE1
-
Acalabrutinib in Combination With R-ICE For Relapsed or Refractory Lymphoma
NCT04189952 ·Status: TERMINATED ·Phase: PHASE2
-
Correlation Analysis of T-lymphocyte Subsets and Prognosis in Autologous Stem Cell Transplantation (ASCT) for Lymphoma
NCT03283111 ·Status: UNKNOWN ·Phase: NA
-
Ofatumumab and Bortezomib for Patients With Low-grade B-cell Non-hodgkin Lymphoma That Relapse After Rituximab
NCT01119794 ·Status: TERMINATED ·Phase: PHASE2
-
Phase 2 Poor Risk DLBCL of TLI and ATG Followed by Matched Allogeneic HT as Consolidation to Autologous HCT
NCT00482053 ·Status: TERMINATED ·Phase: PHASE2
-
Rituximab in Treating Young Patients Who Are Receiving Chemotherapy for B-Cell Non-Hodgkin's Lymphoma or B-Cell Acute Lymphoblastic Leukemia
NCT00324779 ·Status: COMPLETED ·Phase: PHASE2
-
Chemotherapy Plus Rituximab Combination for Adult Lymphoblastic Leukemia (B-ALL) and Burkitt's Non-Hodgkin Lymphoma
NCT01290120 ·Status: COMPLETED ·Phase: PHASE2
-
Whole Body PET-MRI in Paediatric and Adolescent Lymphoma
NCT02935348 ·Status: UNKNOWN
-
Study of Prognostic Factors in Adult Lymphoblastic Lymphoma
NCT03571997 ·Status: UNKNOWN
-
Combination Chemotherapy and Rituximab in Treating Young Patients With Recurrent or Refractory Non-Hodgkin's Lymphoma or Acute Lymphoblastic Leukemia
NCT00058461 ·Status: TERMINATED ·Phase: PHASE2
-
Phase II Study of Dose-Adjusted EPOCH-Rituximab in Adults With Untreated Burkitt Lymphoma and c-MYC+ Diffuse Large B-Cell Lymphoma
NCT01092182 ·Status: COMPLETED ·Phase: PHASE2
-
T-Cell Project: Epidemiologic Component
NCT00705809 ·Status: COMPLETED
-
Study of BGB-A317 in Participants With Relapsed or Refractory Mature T- and NK-cell Neoplasms
NCT03493451 ·Status: COMPLETED ·Phase: PHASE2